cliffwatch

sofosbuvir; velpatasvir; voxilaprevir · Gilead Sciences Inc · NDA 209195

Vosevi

Earliest generic entry, as listed
1 Dec 2037

Blocked by patent: US 11338007.

Listed patents · 47 unexpired

PatentClaimsExpires
US 11338007—1 Dec 2037
US 10912814product1 Jun 2037
US 11338007product, use U-20401 Jun 2037
US 11338007product, use U-20391 Jun 2037
US 11116783—30 Jul 2034
US 9296782substance, product17 Jul 2034
US 11116783product, use U-203930 Jan 2034
US 11116783product, use U-204030 Jan 2034
US 8575135—16 May 2033
US 8921341—16 May 2033
US 8940718—16 May 2033
US 8575135substance, product, use U-203916 Nov 2032
US 8575135substance, product, use U-204016 Nov 2032
US 8921341substance, product, use U-203916 Nov 2032
US 8921341substance, product, use U-204016 Nov 2032
US 8940718substance, product, use U-204016 Nov 2032
US 8940718substance, product, use U-203916 Nov 2032
US 9868745substance, product16 Nov 2032
US 8618076—11 Jun 2031
US 9284342—13 Mar 2031
US 8618076substance, product, use U-203911 Dec 2030
US 8618076substance, product, use U-204011 Dec 2030
US 9284342substance, product, use U-204013 Sep 2030
US 9284342substance, product, use U-203913 Sep 2030
US 7964580—26 Sep 2029
US 8633309—26 Sep 2029
US 8889159—26 Sep 2029
US 7964580substance, product, use U-204026 Mar 2029
US 7964580substance, product, use U-203926 Mar 2029
US 8633309substance, product, use U-204026 Mar 2029
US 8633309substance, product, use U-203926 Mar 2029
US 8889159substance, product, use U-203926 Mar 2029
US 8889159substance, product, use U-204026 Mar 2029
US 8334270—21 Sep 2028
US 8580765—21 Sep 2028
US 8735372—21 Sep 2028
US 9085573—21 Sep 2028
US 8334270substance, product, use U-203921 Mar 2028
US 8334270substance, product, use U-204021 Mar 2028
US 8580765substance, product, use U-203921 Mar 2028
US 8580765substance, product, use U-204021 Mar 2028
US 8735372substance, product, use U-204021 Mar 2028
US 8735372substance, product, use U-203921 Mar 2028
US 8957046use U-203921 Mar 2028
US 8957046use U-204021 Mar 2028
US 9085573substance, product, use U-203921 Mar 2028
US 9085573substance, product, use U-204021 Mar 2028

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
209195 · 001 · RLDtablet, oral400MG;100MG;100MG1 Dec 2037